Receives blood donation
0 CommentsBrantly receives a blood donation from a 14-year-old Ebola survivor in Liberia while awaiting ZMapp, the first person in the current Ebola outbreak to receive the treatment.
What's this? This is an unbiased just-the-facts news timeline ('newsline') about Ebola, created by Newslines contributors. Become a contributor
Ebola is a disease caused by an ebolavirus. Symptoms start two days to three weeks after contracting the virus, with a fever, sore throat, muscle pain and headaches. Vomiting, diarrhea and rash follow, along with decreased function of the liver and kidneys. Victims bleed both within the body and externally. From 1976 through 2013, the World Health Organization reported a total of 1,716 cases. In 2013 an outbreak started in Guinea, spreading to neighboring African countries and infectied doctors, some of who were transported back to the US for treatment. The virus continues to claim victims as it spreads to more countries.
Brantly receives a blood donation from a 14-year-old Ebola survivor in Liberia while awaiting ZMapp, the first person in the current Ebola outbreak to receive the treatment.
Brantly and Writebol are given ZMapp at the hospital in Liberia where they are being treated. After special permission is granted for the use of the untested medicine, the serum is sent from the U.S. stored at subzero temperatures, and must be allowed to thaw naturally for eight to 10 hours. They agree that Writebol will be given the first dose as Brantly is younger and expects to have a better chance of survival. However his condition worsens and he is intravenously administered Writebol’s thawed dose, after telling doctors that he thinks he is dying. Within an hour, his breathing eases and the red rash over his torso fades. Writebol is then given the medicine and requires a second dose, but also recovers.
The Ebola crisis in Liberia worsens after the evacuation of some international medics from Liberia following the infection of two US health workers with the Ebola virus. The overcrowded and understaffed Elwa hospital in the capital, Monrovia, where Kent Brantly and Nancy Writebol worked, has been forced to turn away some Ebola cases.
Health officials say local superstitions are turning away patients from seeking medical care, worsening the outbreak. In Liberia’s Lofa county, health workers trying to screen two communities were chased away with knives and cutlasses, while in other communities Ebola is seen as a ‘curse’ for things like sexual promiscuity. A Red Cross volunteer says some patients favour traditional remedies such as bathing in salt water at midnight. UNICEF Ebola coordinator Fabio Friscia:
What is actually creating the greatest problem is the behavior of the population … It is absolutely something we could expect. The population is being attacked by an absolutely new disease no one [in western Africa] has ever seen before.
The CDC is planning, over the next month, to send 50 epidemiologists, experts of health communication and other service personnel to Sierra Leone and Guinea, which are the hardest hit countries, amid increasing fears of the spread of the deadly Ebola virus to other countries. Dr. Tom Friednen, CDC director:
These individuals will help countries establish emergency operations centers that can develop a structured and effective way of addressing the outbreak.
Researchers consider using blood transfusions from Ebola survivors to pass antibodies into infected people, as no vaccines or drugs are approved yet. Dr. Peter Piot, director of London’s School of Hygiene and Tropical Medicine and co-discoverer of the virus:
This is something that’s fairly simple to do
WHO’s network of international blood regulators says there are thousands of survivors from past Ebola outbreaks in Africa. It says it has identified several patients as possible donors and the first batch of blood from survivors could be available later in the year, but adds:
[The] logistics of blood collection are an issue
Blood from donors must also be screened for other illnesses such as HIV and malaria before it can be used.
The CDC is now concerned about the risk of Ebola spreading beyond Guinea, Nigeria, Sierra Leone and Liberia. Dr. Skinner, an infectious disease specialist from the organization, says that travelers could unknowingly transfer the deadly virus beyond more international borders. Dr. Rob Dretler, CDC:
We know what to do and can completely isolate them but someone coming home who doesn’t know they are sick and is here a few days and gets sick, that’s the risk.
Both US patients appear to be responding well to experimental drugs provided by San Diego-based Mapp Biopharmaceutical. The Company is manufacturing more of the drug, while conducting clinical trials. Larry Zeitlin, the president of Mapp:
It’s absolutely overwhelming. We are discussing with the F.D.A. the right path to make the drug available to people as quickly and safely as possible.
Major decisions on how and where the drug will go are being discussed. Dr. Whaley:
We definitely would like to ramp up to have an impact on the Ebola epidemic. We’re not decision makers on many of these issues. There are regulatory and legal issues that have to be addressed.
The World Bank pledges $200m in emergency aid to Liberia, Guinea and Sierra-Leone, in a bid to counter further spread of the deadly virus. Jim Yong Kim, the president of the World Bank, says that he is ” deeply saddened” by the progress of the epidemic thus far. The funds will be used to undertake numerous relief activities including providing medical supplies, paying staff and driving a campaign that will contain the epidemic.Yong Kim:
I have been monitoring (Ebola’s) deadly impact around the clock and I’m deeply saddened at how it has ravaged health workers, families and communities, disrupted normal life and has led to a breakdown of already weak health systems in the three countries.
Writebol, the second American who contracted Ebola while working with a missionary group in Liberia, is airlifted to Emory hospital in Atlanta for treatment. The aid worker, 59, is the second American to be flown into the US for treatment. David Writebol:
Now we have a real reason to be hopeful.
The World Health Organisation announces it is convening a special meeting next week to explore using experimental drugs in the West African outbreak, after two health workers from the US charity Samaritan’s Purse are treated with a drug called ZMapp. The decision to use an experimental drug to treat two Americans infected with Ebola, while nearly 1 000 Africans have already died from the deadly epidemic, has sparked controversy, but US experts say it is ethically justified.
The experimental drug is still in an extremely early phase of development and had only been tested previously on monkeys. It has never been produced on a large scale. There is no proven treatment or cure for Ebola. Samaritan’s Purse members Kent Brantly and Nancy Writebol, however, have shown improvements since taking the drug.
Nigeria declares a State of Emergency after seven cases of Ebola are confirmed in the country after a man arriving from Liberia fell sick. Two of the confirmed cases die while several people who have come into contact with the man are under surveillance.
A federal Customs and Border Protection agent says the arrival of a sick passenger believed to be from Liberia last Saturday caused confusion at Newark. The flight arrived at the gate and most passengers were allowed into the customs hall, while the sick passenger was taken to a hospital. For a low-level bomb scare, the plane is parked away from the airport.Airport managers went on the public address system and asked the passengers to separate themselves from people who had been on other flights and were not exposed to the vomiting patient.
A panic ensued. It was a disaster
The supply of ZMApp, an experimental Ebola drug has been used to treat the two Americans as well as a Spanish Priest and two Doctors in West African countries is exhausted. Other countries have called ZMapp and they have complied with requests to the best of their ability. The drug has been provided at no cost.
It is our understanding that all patients offered treatment, treated, or expected to be treated were or are highly capable of providing informed consent for the use of an experimental drug not yet evaluated for safety in animals or people.
ZMapp along with their partners are working to increase production as quickly as possible. However, Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases says:
How can a couple of doses control an outbreak with hundreds and hundreds of people? You don’t control the epidemic with two or three doses.
Harvard Medical School associate professor of Global Health and Social Medicine Dr. Scott Podolsky writes in Annals of Internal Medicine that ZMapp is inspired by serology techniques developed in the 1890s after Louis Pasteur and Robert Koch began to identify the agents of diseases like anthrax, diptheria and pneumonia:
From the 1890s onward, this model of production – expose an animal (guinea pig, rabbit, cow, horse, etc.) to an identified microbial pathogen, generate antibodies (or use convalescent serum from former patients), and then ‘passively’ transfer the pre-formed antibodies to an exposed animal or person – could be expanded to such feared and prevalent diseases as pneumococcal pneumonia and meningococcal meningitis.
The San Diego-based Mapp Biopharmaceutical develops ZMapp with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) due to fears Ebola could be used as a bioweapon. ZMapp is made from two serums, MB-003 developed and ZMAb, made by Canadian company Defyrus Inc., and combined by Mapp Biopharmaceutical’s commercial arm LeafBio. MB-003 uses three chimera antibodies developed in mice, with human DNA spliced in, and grown in a genetically engineered indigenous Australian tobacco plant. ZMab was developed in a similar way.
A health care facility in Monrovia, Liberia is attacked, causing a number of patients to flee the facility, all of them infected with Ebola. Some patients chose not to leave. The perpetrators made off with mattresses and equipment. No injuries have been reported. Liberian National Police:
It was an attack from people afraid of Ebola
After Khan’s death, it is discovered that he was not given ZMapp or asked to be a test case although an experimental dose was available. A Canadian team of scientists who had developed ZMapp were testing a dose for resistance to the African climate at a location within reach of the Sierra Leone field hospital where Khan was treated and offered to use it to treat him. However as the drug was untested and Khan’s immune system was fighting the virus, it was decided that the drug had a higher risk of killing him. His colleague, Dr. Daniel Bausch:
You had a person who was sick, and a drug never used on humans before, it wasn’t approved. There were lots of questions to be asked and no easy answers
He believes the final decision was with the field doctors at the hospital but says he disagrees with the refusal of the drug, especially as it was used on :
I do want it to be clear that these were difficult, delicate decisions that people in a stressful situation had to make. But I’m not going to deny that I disagree with the decision they made.
Kenya will be closing its borders on Wednesday August 20 to people travelling from Guinea, Sierra Leone and Liberia due to the spread of the virus. Kenya is at high risk as it is a major transport hub. Kenya’s health secretary said Kenyans and medical workers flying in from those states would still be allowed in. Kenyan Airways says it will stop flights to Liberia and Sierra Leone when the ban comes in. Kenyan Health Minister James Macharia said it was “in the interest of public health” and warned that Kenyans and health workers who had returned from the three west African states would face “strict checks” and would be quarantined if necessary.
Brantly is released from Hospital. He releases a statement (full text):
Today is a miraculous day. I am thrilled to be alive, to be well and to be reunited with my family. As a medical missionary, I never imagined myself in this position. When my family and I moved to Liberia last October to begin a two-year term working with Samaritan’s Purse, Ebola was not on the radar. We moved to Liberia because God called us to serve the people of Liberia.
After taking Amber and our children to the airport to return to the States on Sunday morning, July 20, I poured myself into my work even more than before—transferring patients to our new, bigger isolation unit; training and orienting new staff; and working with our Human Resources officer to fill our staffing needs. Three days later, on Wednesday, July 23, I woke up feeling under the weather, and then my life took an unexpected turn as I was diagnosed with Ebola Virus Disease. As I lay in my bed in Liberia for the following nine days, getting sicker and weaker each day, I prayed that God would help me to be faithful even in my illness, and I prayed that in my life or in my death, He would be glorified.
I did not know then, but I have learned since, that there were thousands, maybe even millions of people around the world praying for me throughout that week, and even still today. I cannot thank you enough for your prayers and your support. But what I can tell you is that I serve a faithful God who answers prayers.
Thank you to Emory University Hospital and especially to the medical staff in the isolation unit. You treated me with such expertise, yet with such tenderness and compassion. For the last three weeks you have been my friends and my family. And so many of you ministered to me not only physically, but also spiritually, which has been an important part of my recovery. I will never forget you and all that you have done for me. And thank you to my family, my friends, my church family and to all who lifted me up in prayer, asking for my healing and recovery. Please do not stop praying for the people of Liberia and West Africa, and for a quick end to this Ebola epidemic.
Newslines aims to give readers the complete unbiased news history of any topic. Become a contributor to add news about your favourite topic.
© The Social News Company Ltd.
Registered in Scotland: SC532497
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
OKLearn more×We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them: